AI Article Synopsis
- Continuous cell division is a key feature of cancer, making cell-cycle regulators, like cyclins, important targets for cancer therapy.
- Cyclins A, B, and D are especially promising because they are often overexpressed in tumors but have low expression in normal tissues, making them potential candidates for developing immune-based treatments.
- The review suggests that targeting the cyclin family might represent a new approach for creating tumor antigens for cancer treatment and prevention.
Article Abstract
Continuous cell division is a hallmark of cancer and cell-cycle regulators therefore represent relevant target molecules for tumor therapy. Among these targets the cyclins are of particular interest as they are overexpressed in various tumor entities with little expression in normal tissue. Here we review evidence that these molecules are recognized by the immune system, summarize why cyclins A, B and D in particular appear to be interesting targets for active and passive immunotherapy, and discuss whether the entire family could be an interesting novel class of tumor antigens for cancer treatment and prevention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/erv.10.170 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!